HC Wainwright & Co. Reiterates Buy on G1 Therapeutics, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on G1 Therapeutics (NASDAQ:GTHX) and maintained a $9 price target.
May 28, 2024 | 4:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on G1 Therapeutics and maintained a $9 price target, indicating continued confidence in the company's stock.
The reiteration of a Buy rating and the maintenance of a $9 price target by a reputable analyst can boost investor confidence and potentially lead to a short-term increase in the stock price of G1 Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100